Atropine Sulfate
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Atropine Sulfate |
| DrugBank ID | DB00572 |
| Brand Names (EU) | Ryjunea |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.56% |
Approved Indication (EMA)
Ryjunea is indicated for slowing the progression of myopia in paediatric patients. Treatment may be initiated in children aged 3-14 years with a progression rate of 0.5 D or more per year and a severity of -0.5 D to -6.0 D.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | migraine disorder | 99.56% | DL |
| 2 | migraine with brainstem aura | 99.42% | DL |
| 3 | migraine with or without aura, susceptibility to | 98.15% | DL |
| 4 | atrophoderma vermiculata | 98.15% | DL |
| 5 | open-angle glaucoma | 98.03% | DL |
| 6 | primary hereditary glaucoma | 97.78% | DL |
| 7 | ulerythema ophryogenesis | 97.76% | DL |
| 8 | headache disorder | 97.24% | DL |
| 9 | trigeminal autonomic cephalalgia | 96.46% | DL |
| 10 | nephrogenic syndrome of inappropriate antidiuresis | 96.34% | DL |
| 11 | diffuse alopecia areata | 95.28% | DL |
| 12 | hypertrichosis (disease) | 95.27% | DL |
| 13 | congenital hypotrichosis milia | 95.23% | DL |
| 14 | alopecia | 95.14% | DL |
| 15 | Ambras type hypertrichosis universalis congenita | 95.13% | DL |
| 16 | common cold | 95.10% | DL |
| 17 | hypotrichosis simplex of the scalp | 94.99% | DL |
| 18 | sciatic neuropathy | 94.73% | DL |
| 19 | malformation syndrome with odontal and/or periodontal component | 94.63% | DL |
| 20 | syndrome with a Dandy-Walker malformation as major feature | 94.56% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.